2025 Annual Review：Where Technology Meets Precision Medicine Innovation

In 2025, YZY MED solidified technological innovation as its core driving force, achieving comprehensive breakthroughs across the field of precision medicine.

A Year of Pioneering Product Launches and R&D Milestones

The company secured registration certificates for four Class III medical devices. The simultaneous approval of our independently developed BCR/ABL and *AML1/ETO* Fusion Gene Detection Kits (Fluorescence In Situ Hybridization) marked a milestone achievement in the molecular diagnosis of hematological tumors. We further enriched our product pipeline: the Human SDC2 Gene Methylation Detection Kit opened a new chapter in non-invasive, accurate, and convenient early tumor screening through epigenetic technology; the Human CYP2D6 Gene Detection Kit expanded our pharmacogenomic portfolio, providing more comprehensive genetic evidence to support multidisciplinary clinical medication guidance.
Through forward-looking investments in multi-omics, multi-modal precision detection, and AI analytics, we successfully built a novel molecular POCT technology platform, accelerating the development of AI-assisted diagnostic tools that integrate molecular and cytopathological insights.
Our collaborative research with top domestic clinical teams yielded authoritative results, confirming that combining our CTC detection technology with imaging significantly improves the efficiency of differentiating benign from malignant pulmonary nodules. This expands the clinical application of our cutting-edge CTC separation and enrichment technology.
Intellectual property achievements were robust: with 18 new patents applied for and 12 authorized in 2025, our cumulative totals now exceed 170 applications and 90 authorized patents, reflecting a qualitative leap in our innovative output.

Strategic Market Expansion and Global Engagement

We actively shaped industry discourse by participating in major domestic and international forums. Domestically, our longstanding presence at events like the CSCO Annual Meeting, Shanghai CMEF, CACLP, and the National Pathology Annual Meeting reinforced our role in advancing standardized tumor diagnosis and showcasing innovative solutions.
Globally, we made significant strides by engaging key markets at Medlab Middle East 2025, connecting with the Southeast Asian ecosystem via WHX Labs Kuala Lumpur, and dialoguing with global leaders at MEDICA 2025.
We also convened the “Gathering Precision, Personalized Medication” academic salon, bringing together experts to foster the standardized development of precision pharmacogenomics.

Leading with Responsibility and Core Technology

Empowering industry development with professional strength and building industry consensus through academic exchanges, YZY MED demonstrated the industry responsibility of a benchmark enterprise with practical actions in 2025.

Its core technological achievements have set the industry benchmark: the independently developed and continuously upgraded CTCBIOPSY Circulating Tumor Cell Detection System, as the only domestic device in the field of tumor liquid biopsy, was included in the 2025 Green Book on the Development Status and Trends of China’s Medical Equipment. It provides solid technical support for building a full-course management ecosystem of tumor diagnosis and treatment from “early warning” to “precision intervention”.

Charting the Future: Strategic Clarity and Organizational Vitality

To ensure sustainable growth, we meticulously charted our course forward through the 2026-2028 Three-Year Strategic Planning Seminar. We clarified our dual-core mission: to be “the leader in China’s pharmacogenomic testing industry and the provider of integrated solutions for tumor precision testing.” Our multi-dimensional strategy focuses on technological deepening, precision marketing, and operational efficiency.
To execute this vision, we are upgrading our digital infrastructure, optimizing organizational structures, and revitalizing our talent system. By empowering our leadership, marketing, and R&D teams, and fostering a culture of continuous learning, we are building a resilient organization poised for synchronized growth with our people.

Looking Ahead

2025 was a year of solid achievement and strategic positioning for YZY MED. As we move forward, we remain committed to leveraging innovation to improve patient outcomes and drive the future of precision medicine across the globe.